Innovation Scorecard
By
GlobalData's “Innovation Scorecard 2022” report presents a four-quadrant analysis for identifying Leaders, Challengers, Laggards, and disruptive sectors and themes based on their Innovation Performance. With this report, we are also releasing a global ranking of public companies based on our innovation performance index specific to a sector.
GlobalData’s Innovation Scorecard leverages in-house alternative datasets (patents, deals, jobs, etc.) and enriched industrial and thematic taxonomy to benchmark companies following our proprietary 3I framework (Intensity, Impact, Ingenuity) across geographies, sectors, and themes. This framework is intended to help our clients make informed investment decisions by predicting the winners and losers in relevant sectors of the company’s IP portfolio.
Key findings from this year’s report include:
- 1. Meta’s rank has improved from 13 in the last ten years to eight in the last three years which indicates it has invested more in R&D and filed more quality patents. There are some notable new entrants in the top 20 clubs as Kia, Baidu, Boeing, Hyundai, Capital One, and Johnson & Johnson.
- 2. Corporate venture capital (CVC) activity is accelerated by US, Japanese and Chinese firms which indicates high activity in innovation. Companies like Tencent Holdings, Goldman Sachs, and Softbank are leaders in CVC. The financial service sector is the most preferred sector by venture capitalists.
- 3. Samsung is the only South Korean company that could make the top ten lists in the technology sector, which is predominately ruled by the companies having their headquarters in the US.
- 4. Johnson & Johnson, Roche, and Bayer are the top three most innovative companies in the pharma and healthcare sector.
- 5. Four quadrant analysis indicates that Boeing maintains itself as a disruptive leader in aerospace, defense & security, and is being challenged by companies like QinetIQ Group and Kratos.
- • What are the most investable emerging Technologies/Themes, and which companies are most actively protecting IP therein. Can "Innovation-Alpha" be derived to validate such opportunities?
- • Which publicly listed, private and startup companies can be a good target for M&A, and can we estimate their creditworthiness?
- • How companies have evolved their patent portfolio, based on point-in-time ownership of Patents and how have they sustained/diversified innovation monopoly in certain technologies?
- • How Patent Portfolio Strength can be evaluated based on Citations data and other patient-derived indicators and benchmark innovation performance amongst peers?
- • How to Identify qualifiable sales leads for Patent prosecution and litigation services providers?